SECUKINUMAB

Biological Novartis Pharma AG
Total Payments
$18,637
Transactions
18
Doctors
7
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2018 $15,262 16 6
2017 $3,375 2 2

Payments by Nature

Nature of Payment Amount Transactions Share
Travel and Lodging $8,530 5 45.8%
Unspecified $6,731 10 36.1%
Consulting Fee $3,240 1 17.4%
Food and Beverage $136.60 2 0.7%

Payments by Type

General
$11,906
8 transactions
Research
$6,731
10 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Publication support research related Novartis Pharma AG $6,731 4

Top Doctors Receiving Payments for SECUKINUMAB

Doctor Specialty Location Total Records
, M.D Dermatology Somers, NY $11,579 4
, MD Rheumatology Portland, OR $2,623 3
, MD Rheumatology Duncansville, PA $1,688 1
, M.D Rheumatology Portola Valley, CA $1,678 4
, MD Internal Medicine Salt Lake City, UT $743.17 2
, MD Rheumatology Chicago, IL $197.49 2
, M.D Allergy & Immunology La Jolla, CA $129.20 2

About SECUKINUMAB

SECUKINUMAB is a biological associated with $18,637 in payments to 7 healthcare providers, recorded across 18 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.

Payment data is available from 2017 to 2018. In 2018, $15,262 was paid across 16 transactions to 6 doctors.

The most common payment nature for SECUKINUMAB is "Travel and Lodging" ($8,530, 45.8% of total).

SECUKINUMAB is associated with 1 research study, including "Publication support research related" ($6,731).